Patients with tumors in the trigone and urethra were more likely to experience recurrence and cancer-specific death after radical cystectomy than patients with tumor only in the bladder walls. The ...
NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer ...
“We believe Trigone’s novel intravesicular sustained-release formulation could enable NDV-01 to be a first-line therapy for non-muscle invasive bladder cancer, supported by several differentiators ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results